Description
A dual GLP-1/GIP receptor agonist (peptide based on exendin-4) that powerfully improves glycemic control and induces weight loss. Tirzepatide (FDA-approved as Mounjaro® for diabetes) can reduce body weight by ~20% by enhancing insulin secretion (via GLP-1 & GIP) and markedly suppressing appetite. 5 mg vials allow initial dose-range finding in obesity models. It improves insulin sensitivity and has shown superior effects to GLP-1 alone in clinical studies.




Reviews
There are no reviews yet.